Gain Therapeutics to Attend the 2026 Maxim Growth Summit
Globe Newswire•08/10/2026•07:00 ET
0
Key Highlights
- ➤Gain Therapeutics (GANX) will meet institutional investors at the 2026 Maxim Growth Summit.
- ➤2026 Maxim Growth Summit runs October 12-14 at New York’s Hard Rock Hotel.
- ➤Rexaceract is in a Phase 1b trial for Parkinson’s disease with or without GBA1 mutations.
- ➤Rexaceract has potential applications in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease.
BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12(th) to 14(th) at The Hard Rock Hotel New York, in New York City.
Gain Therapeutics will be meeting with institutional investors in one-on-one meeting sessions and engaging with senior Maxim research analysts throughout the event.
Get started
Create a free account to read the full story.